Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
Healthcare
$3.99 -0.81%
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
52W Low $2.78High $6.45
Volume 0.34M
Average 0.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$132.03M
FY 2025 · Annual
Investing Cash Flow
$188.79M
FY 2025 · Annual
+236.5% YoYFinancing Cash Flow
-$25.75M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 121.19M | (115.91M) | (135.96M) | (168.39M) | (158.35M) |
| Depreciation & Amortization | 29K | 260K | 416K | 416K | 416K |
| Deferred Income Tax | (29.39M) | 0 | (48.56M) | 0 | (6.36M) |
| Stock-Based Compensation | 39.62M | 46.72M | 49.43M | 51.77M | 20.72M |
| Change in Working Capital | (247.85M) | (46.59M) | 16.16M | (7.48M) | 16.48M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.29M | (1.98M) | 1.7M | 206K | 8.49M |
| Other Working Capital | (258.13M) | (44.6M) | 14.46M | (7.68M) | 8M |
| Other Non-Cash Items | 29.39M | (5.47M) | 33.11M | (11.82M) | (4.94M) |
| Operating Cash Flow | (87.01M) | (120.98M) | (85.4M) | (135.5M) | (132.03M) |
| Capital Expenditures | (4K) | (1.94M) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 453.47K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (545.35M) | (562.36M) | (461.18M) | (281.94M) |
| Sales of Investments | 0 | 91.89M | 602.67M | 517.28M | 470.73M |
| Other Investing Activities | 0 | (453.47K) | 0 | 0 | 0 |
| Investing Cash Flow | (4K) | (455.41M) | 40.3M | 56.11M | 188.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.47M | 230K | 257K | 267K | 259K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.52M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 140K | 0 | 0 | (485K) |
| Financing Cash Flow | 1.47M | 370K | 257K | 267K | (25.75M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (85.54M) | (576.02M) | (44.84M) | (79.13M) | 31.02M |
| Free Cash Flow | (87.01M) | (122.93M) | (85.4M) | (135.5M) | (132.03M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$158.3M
+ D&A$416.0K
+ Stock-Based Comp$20.7M
- Deferred Tax-$6.4M
+ Working Capital$16.5M
- Other Non-Cash-$4.9M
= Operating Cash Flow-$132.0M
- Capex$0
= Free Cash Flow-$132.0M
Analysis
FY2025 free cash flow is -$132.0M. FCF conversion is 83.4% of net income. Operating cash flow was -$132.0M, with capex of $0. The largest bridge item is Stock-Based Comp at $20.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 |
Does AVIR generate free cash flow?
Atea Pharmaceuticals, Inc. (AVIR) generated -$132.03M of free cash flow in fiscal 2025.
How much operating cash flow does AVIR produce?
Operating cash flow was -$132.03M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.